Relapsing intracranial germ cell tumours warrant retreatment. (September 2020)

• Record Type: Journal Article
• Authors: Callec, Laetitia; Lardy-Cleaud, Audrey; Guerrini-Rousseau, Lea; Alapetite, Claire; Vignon, Laure; Chastagner, Pascal; Frappaz, Didier; Faure-Conter, Cecile
• Is Part Of: European journal of cancer. Volume 136(2020)
• Page Start: 186
• Page End: 194
• Publication Date: 2020-09
• Subjects: Germinoma -- Non-germinoma germ cell tumours -- Relapse -- High-dose chemotherapy -- Radiotherapy -- Outcome; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2020.06.012
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: The optimal therapeutic strategy for relapsing intracranial germ cell tumours (IGCTs) has not been clearly established. Methods: Relapses of IGCTs, occurring from 01/01/1990 to 31/12/2014, were retrieved from the Societe Française d'Oncologie Pediatrique-TGM 90, 92 and GCT 96 protocols, and from the National Childhood Solid Tumour Registry. Refractory IGCTs were excluded. Results: Forty-four relapsing IGCTs were identified: 14 were initially treated for histologically proven germinomas (germinoma group), 5 for non-histologically proven germinomas (putative germinoma group) and 25 for non-germinomatous germ cell tumours (NGGCTs) (NGGCT group). In the germinoma group, the 5-year event-free survival (EFS) and overall survival (OS) were 79% (95% confidence interval [CI]: 47–93) and 86% (95% CI: 54–96), respectively. Only one of the 11 patients treated with reirradiation experienced a further relapse. A trend of better EFS was observed for relapses at sites that were not initially involved: 5-year EFS of 100% versus 67% (95% CI: 28–88), p = 0.09. In the putative germinoma group, 4 of 5 patients experienced a further event, leading to 2 deaths. In the NGGCT group, the 5-year EFS and OS were 56% (95% CI: 35–73) and 60% (95% CI: 38–76), respectively. A significant improvement in outcomes after high-dose chemotherapy (HDC) was observed: 5-year OS of 72% (95% CI: 46–87) versus 29% (95% CI: 4–61), p = 0.006. Conclusion: Relapsing germinomas are highly curable; reirradiation appears to play a key role. Histological proof at initial diagnosis if markers are negative is crucial. Despite inferior outcomes relapsing, NGGCTs can be cured in a significant proportion of cases provided intensive treatment including HDC is applied. Highlights: Histology at diagnosis and at relapse has an impact on prognosis. Relapsing germinomas are highly curable; reirradiation appears to play a key role. In this group, high-dose chemotherapy (HDC) with reirradiation may be overtreatment. Recurrent non-germinomatous germ cell tumours have a less favourable prognosis. In this group, both HDC and reirradiation are required for cure.